Arrowhead Pharmaceuticals (ARWR) Upgraded to “Sell” by ValuEngine

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.

Several other equities research analysts have also recently commented on ARWR. Jefferies Group reaffirmed a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price objective (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. William Blair raised Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th. Finally, Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective on the stock in a research report on Monday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.70.

Shares of Arrowhead Pharmaceuticals (ARWR) traded up $0.03 during trading hours on Thursday, hitting $3.57. The stock had a trading volume of 1,181,040 shares, compared to its average volume of 972,484. Arrowhead Pharmaceuticals has a 1 year low of $1.20 and a 1 year high of $4.54. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03.

A number of large investors have recently made changes to their positions in ARWR. ING Groep NV purchased a new position in Arrowhead Pharmaceuticals in the third quarter worth about $3,500,000. Allianz Asset Management GmbH purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $1,958,000. LMR Partners LLP purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at about $467,000. UBS Asset Management Americas Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 414.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 53,500 shares in the last quarter. Finally, Virtu KCG Holdings LLC lifted its position in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares in the last quarter. 20.20% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals (ARWR) Upgraded to “Sell” by ValuEngine” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/30/arrowhead-pharmaceuticals-arwr-upgraded-to-sell-by-valuengine.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply